share_log

Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024

Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024

modern預計將於2024年11月7日星期四公佈2024年第三季度財務業績
Accesswire ·  10/17 07:05

CAMBRIDGE, MA / ACCESSWIRE / October 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 7, 2024 to report its third quarter 2024 financial results, and provide a corporate update.

馬薩諸塞州劍橋 / ACCESSWIRE / 2024年10月17日 / moderna公司(納斯達克:MRNA)今天宣佈,將於2024年11月7日星期四上午8:00舉行現場電話會議和網絡直播,發佈2024年第三季度財務業績,並提供公司更新。

A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.

有關通話的現場網絡直播將在moderna網站的投資者部分的「活動和展示」下提供。

  • Webcast:

  • 網絡直播:

The archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.

電話會議後大約兩個小時,將在現代(Moderna)的網站上提供存檔的網絡直播,並將在電話會議後的一年內提供。

About Moderna

關於現代

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Moderna是mRNA醫學領域的領軍者。通過推動mRNA技術的進步,現代正在重新構想藥物的製造方式,爲所有人治療和預防疾病。通過在科學、技術和健康交叉領域工作十多年,公司已以前所未有的速度和效率開發出藥物,包括最早和最有效的COVID-19疫苗之一。

Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Moderna的mRNA平台使得感染性疾病、免疫治療、罕見病和自身免疫性疾病的治療和疫苗的開發成爲可能。Moderna擁有獨特的文化和全球團隊,秉持Moderna價值觀和思維方式,爲了負責任地改變人們未來的健康而努力,致力於通過mRNA藥物帶來最大的影響。有關Moderna的更多信息,請訪問modernatx.com,並在X(原Twitter)、Facebook、Instagram、YouTube和LinkedIn上與我們聯繫。

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

投資者:
Lavina Talukdar
高級副主席,投資者關係負責人
617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

來源:現代RNA股份有限公司。


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論